Compare · CWBR vs QDEL

CWBR vs QDEL

Side-by-side comparison of CohBar Inc. (CWBR) and QuidelOrtho Corporation (QDEL): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CWBR and QDEL operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
  • QDEL carries a market cap of $677.2M.
  • QDEL has hit the wire 4 times in the past 4 weeks while CWBR has been quiet.
  • QDEL has more recent analyst coverage (19 ratings vs 1 for CWBR).
MetricCWBRQDEL
Company
CohBar Inc.
QuidelOrtho Corporation
Price
-
-
Market cap
-
$677.2M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Exchange
NASDAQ
NASDAQ
IPO
News (4w)
0
4
Recent ratings
1
19
CWBR

CohBar Inc.

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, acute respiratory distress syndrome, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases, CB5064 analogs for COVID-19 associated ARDS, MBT5 analogs for CXCR4-related cancer and orphan diseases, and MBT3 analogs for cancer immunotherapy. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.

QDEL

QuidelOrtho Corporation

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; and Virena, a wireless cellular data management and surveillance system The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California.

Latest CWBR

Latest QDEL